Condition: Chronic Lymphocytic Leukemia · Sponsor: AstraZeneca
Interested? Contact the study team ↓
to address critical gap in knowledge, providing essential data on the real-world effectiveness, safety, associated with acalabrutinib treatment in patients with CLL
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Age ≥18 years. * Confirmed diagnosis of CLL. * Newly prescribed acalabrutinib monotherapy within the previous four weeks preceding study enrolment. Monotherapy is defined as acalabrutinib prescribes without concomitant administration (or planned initiation) of other anti-leukemic agents (e.g. obinutuzumab, venetoclax, bendamustine) within ± 30 days of acalabrutinib initiation. * Treatment-naïve or R/R CLL. * Ability and willingness to provide informed consent for study participation. Exclusion Criteria: * Patients not satisfying any of the inclusion criteria. * Prior treatment with any BTK inhibitor. * Participation in other ongoing clinical trials. * Pregnant or breastfeeding females
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Research Site | Grodno, Belarus | Not Yet Recruiting |
| Research Site | Homyel, Belarus | Not Yet Recruiting |
| Research Site | Minsk, Belarus | Recruiting |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.